• Advanced Biomed entered a deal on June 30, 2026 to sell its Taiwan subsidiary to an unrelated third party for US$ 490,000.
• The unit houses biomedical R&D operations, including the A+PerfusC integrated perfusion 3D cell culture platform.
• Closing is expected within three months of the agreement date.
• Advanced Biomed plans to continue other operations, including AI-focused activities through Acellent Technologies (Hong Kong).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advanced Biomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073735), on June 30, 2026, and is solely responsible for the information contained therein.